Selected research
Industry Research
Scopolamine Hydrobromide Industry Research Report 2026
Market perspective
The global Scopolamine Hydrobromide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Scopolamine Hydrobromide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Scopolamine Hydrobromide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Scopolamine Hydrobromide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Scopolamine Hydrobromide include Accord Healthcare, Alchem International, ALKALOIDS CORPORATION, Baxter International, BioCrick, ChemFaces, FUJIFILM Wako, Glentham Life Sciences and Manus Aktteva Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Scopolamine Hydrobromide market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Scopolamine Hydrobromide Market by Company
Accord Healthcare
Alchem International
ALKALOIDS CORPORATION
Baxter International
BioCrick
ChemFaces
FUJIFILM Wako
Glentham Life Sciences
Manus Aktteva Biopharma
Sigma-Aldrich
TCI Chemicals
Tocris Bioscience
Amgen
Mylan
Novartis
Sandoz
Teva Pharmaceuticals
Scopolamine Hydrobromide Segment by Type
Injections
Topical
Oral
Scopolamine Hydrobromide Segment by Application
Hospital
Clinic
Scopolamine Hydrobromide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Scopolamine Hydrobromide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Scopolamine Hydrobromide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Scopolamine Hydrobromide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Scopolamine Hydrobromide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Scopolamine Hydrobromide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Scopolamine Hydrobromide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injections
- Topical
- Oral
Applications
- Hospital
- Clinic
Companies covered
- Accord Healthcare
- Alchem International
- ALKALOIDS CORPORATION
- Baxter International
- BioCrick
- ChemFaces
- FUJIFILM Wako
- Glentham Life Sciences
- Manus Aktteva Biopharma
- Sigma-Aldrich
- TCI Chemicals
- Tocris Bioscience
- Amgen
- Mylan
- Novartis
- Sandoz
- Teva Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Scopolamine Hydrobromide Market Size (2021-2032)
- 2.2.2 Global Scopolamine Hydrobromide Sales (2021-2032)
- 2.2.3 Global Scopolamine Hydrobromide Market Average Price (2021-2032)
- 2.3 Scopolamine Hydrobromide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injections
- 2.3.3 Topical
- 2.3.4 Oral
- 2.4 Scopolamine Hydrobromide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Scopolamine Hydrobromide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Scopolamine Hydrobromide Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Scopolamine Hydrobromide Revenue of Manufacturers (2021-2026)
- 3.4 Global Scopolamine Hydrobromide Average Price by Manufacturers (2021-2026)
- 3.5 Global Scopolamine Hydrobromide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Scopolamine Hydrobromide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Scopolamine Hydrobromide, Product Type & Application
- 3.8 Global Manufacturers of Scopolamine Hydrobromide, Established Date
- 3.9 Global Scopolamine Hydrobromide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Accord Healthcare
- 4.1.1 Accord Healthcare Company Information
- 4.1.2 Accord Healthcare Business Overview
- 4.1.3 Accord Healthcare Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Accord Healthcare Scopolamine Hydrobromide Product Portfolio
- 4.1.5 Accord Healthcare Recent Developments
- 4.2 Alchem International
- 4.2.1 Alchem International Company Information
- 4.2.2 Alchem International Business Overview
- 4.2.3 Alchem International Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Alchem International Scopolamine Hydrobromide Product Portfolio
- 4.2.5 Alchem International Recent Developments
- 4.3 ALKALOIDS CORPORATION
- 4.3.1 ALKALOIDS CORPORATION Company Information
- 4.3.2 ALKALOIDS CORPORATION Business Overview
- 4.3.3 ALKALOIDS CORPORATION Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 ALKALOIDS CORPORATION Scopolamine Hydrobromide Product Portfolio
- 4.3.5 ALKALOIDS CORPORATION Recent Developments
- 4.4 Baxter International
- 4.4.1 Baxter International Company Information
- 4.4.2 Baxter International Business Overview
- 4.4.3 Baxter International Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Baxter International Scopolamine Hydrobromide Product Portfolio
- 4.4.5 Baxter International Recent Developments
- 4.5 BioCrick
- 4.5.1 BioCrick Company Information
- 4.5.2 BioCrick Business Overview
- 4.5.3 BioCrick Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BioCrick Scopolamine Hydrobromide Product Portfolio
- 4.5.5 BioCrick Recent Developments
- 4.6 ChemFaces
- 4.6.1 ChemFaces Company Information
- 4.6.2 ChemFaces Business Overview
- 4.6.3 ChemFaces Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ChemFaces Scopolamine Hydrobromide Product Portfolio
- 4.6.5 ChemFaces Recent Developments
- 4.7 FUJIFILM Wako
- 4.7.1 FUJIFILM Wako Company Information
- 4.7.2 FUJIFILM Wako Business Overview
- 4.7.3 FUJIFILM Wako Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 FUJIFILM Wako Scopolamine Hydrobromide Product Portfolio
- 4.7.5 FUJIFILM Wako Recent Developments
- 4.8 Glentham Life Sciences
- 4.8.1 Glentham Life Sciences Company Information
- 4.8.2 Glentham Life Sciences Business Overview
- 4.8.3 Glentham Life Sciences Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Glentham Life Sciences Scopolamine Hydrobromide Product Portfolio
- 4.8.5 Glentham Life Sciences Recent Developments
- 4.9 Manus Aktteva Biopharma
- 4.9.1 Manus Aktteva Biopharma Company Information
- 4.9.2 Manus Aktteva Biopharma Business Overview
- 4.9.3 Manus Aktteva Biopharma Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Manus Aktteva Biopharma Scopolamine Hydrobromide Product Portfolio
- 4.9.5 Manus Aktteva Biopharma Recent Developments
- 4.10 Sigma-Aldrich
- 4.10.1 Sigma-Aldrich Company Information
- 4.10.2 Sigma-Aldrich Business Overview
- 4.10.3 Sigma-Aldrich Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sigma-Aldrich Scopolamine Hydrobromide Product Portfolio
- 4.10.5 Sigma-Aldrich Recent Developments
- 4.11 TCI Chemicals
- 4.11.1 TCI Chemicals Company Information
- 4.11.2 TCI Chemicals Business Overview
- 4.11.3 TCI Chemicals Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 TCI Chemicals Scopolamine Hydrobromide Product Portfolio
- 4.11.5 TCI Chemicals Recent Developments
- 4.12 Tocris Bioscience
- 4.12.1 Tocris Bioscience Company Information
- 4.12.2 Tocris Bioscience Business Overview
- 4.12.3 Tocris Bioscience Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Tocris Bioscience Scopolamine Hydrobromide Product Portfolio
- 4.12.5 Tocris Bioscience Recent Developments
- 4.13 Amgen
- 4.13.1 Amgen Company Information
- 4.13.2 Amgen Business Overview
- 4.13.3 Amgen Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Amgen Scopolamine Hydrobromide Product Portfolio
- 4.13.5 Amgen Recent Developments
- 4.14 Mylan
- 4.14.1 Mylan Company Information
- 4.14.2 Mylan Business Overview
- 4.14.3 Mylan Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Mylan Scopolamine Hydrobromide Product Portfolio
- 4.14.5 Mylan Recent Developments
- 4.15 Novartis
- 4.15.1 Novartis Company Information
- 4.15.2 Novartis Business Overview
- 4.15.3 Novartis Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Novartis Scopolamine Hydrobromide Product Portfolio
- 4.15.5 Novartis Recent Developments
- 4.16 Sandoz
- 4.16.1 Sandoz Company Information
- 4.16.2 Sandoz Business Overview
- 4.16.3 Sandoz Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Sandoz Scopolamine Hydrobromide Product Portfolio
- 4.16.5 Sandoz Recent Developments
- 4.17 Teva Pharmaceuticals
- 4.17.1 Teva Pharmaceuticals Company Information
- 4.17.2 Teva Pharmaceuticals Business Overview
- 4.17.3 Teva Pharmaceuticals Scopolamine Hydrobromide Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Teva Pharmaceuticals Scopolamine Hydrobromide Product Portfolio
- 4.17.5 Teva Pharmaceuticals Recent Developments
5 Global Scopolamine Hydrobromide Market Scenario by Region
- 5.1 Global Scopolamine Hydrobromide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Scopolamine Hydrobromide Sales by Region: 2021-2032
- 5.2.1 Global Scopolamine Hydrobromide Sales by Region: 2021-2026
- 5.2.2 Global Scopolamine Hydrobromide Sales by Region: 2027-2032
- 5.3 Global Scopolamine Hydrobromide Revenue by Region: 2021-2032
- 5.3.1 Global Scopolamine Hydrobromide Revenue by Region: 2021-2026
- 5.3.2 Global Scopolamine Hydrobromide Revenue by Region: 2027-2032
- 5.4 North America Scopolamine Hydrobromide Market Facts & Figures by Country
- 5.4.1 North America Scopolamine Hydrobromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Scopolamine Hydrobromide Sales by Country (2021-2032)
- 5.4.3 North America Scopolamine Hydrobromide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Scopolamine Hydrobromide Market Facts & Figures by Country
- 5.5.1 Europe Scopolamine Hydrobromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Scopolamine Hydrobromide Sales by Country (2021-2032)
- 5.5.3 Europe Scopolamine Hydrobromide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Scopolamine Hydrobromide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Scopolamine Hydrobromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Scopolamine Hydrobromide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Scopolamine Hydrobromide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Scopolamine Hydrobromide Market Facts & Figures by Country
- 5.7.1 South America Scopolamine Hydrobromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Scopolamine Hydrobromide Sales by Country (2021-2032)
- 5.7.3 South America Scopolamine Hydrobromide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Scopolamine Hydrobromide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Scopolamine Hydrobromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Scopolamine Hydrobromide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Scopolamine Hydrobromide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Scopolamine Hydrobromide Sales by Type (2021-2032)
- 6.1.1 Global Scopolamine Hydrobromide Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Scopolamine Hydrobromide Sales Market Share by Type (2021-2032)
- 6.2 Global Scopolamine Hydrobromide Revenue by Type (2021-2032)
- 6.2.1 Global Scopolamine Hydrobromide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Scopolamine Hydrobromide Revenue Market Share by Type (2021-2032)
- 6.3 Global Scopolamine Hydrobromide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Scopolamine Hydrobromide Sales by Application (2021-2032)
- 7.1.1 Global Scopolamine Hydrobromide Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Scopolamine Hydrobromide Sales Market Share by Application (2021-2032)
- 7.2 Global Scopolamine Hydrobromide Revenue by Application (2021-2032)
- 7.2.1 Global Scopolamine Hydrobromide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Scopolamine Hydrobromide Revenue Market Share by Application (2021-2032)
- 7.3 Global Scopolamine Hydrobromide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Scopolamine Hydrobromide Value Chain Analysis
- 8.1.1 Scopolamine Hydrobromide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Scopolamine Hydrobromide Production Mode & Process
- 8.2 Scopolamine Hydrobromide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Scopolamine Hydrobromide Distributors
- 8.2.3 Scopolamine Hydrobromide Customers
9 Global Scopolamine Hydrobromide Analyzing Market Dynamics
- 9.1 Scopolamine Hydrobromide Industry Trends
- 9.2 Scopolamine Hydrobromide Industry Drivers
- 9.3 Scopolamine Hydrobromide Industry Opportunities and Challenges
- 9.4 Scopolamine Hydrobromide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst